Strategy | Total cost | LY | QALY | ICERa |
---|---|---|---|---|
Vemurafenib + cobimetinib | 353,457 | 2.34 | 1.96 | Dominate |
Encorafenib + binimetinib | 588,988 | 2.64 | 2.22 | Dominated |
Dabrafenib + trametinib | 455,573 | 2.72 | 2.28 | 325,113 |
Atezolizumab + vemurafenib + cobimetinib | 683,381 | 2.83 | 2.38 | 2,247,500 |